Danazol as first-line therapy for myelodysplastic syndromes
Conclusion Danazol as frontline therapy is an acceptable treatment option with low side effects for patients with MDS that cannot receive ASCT Teaser At present, no standard therapy is available for most patients with myelodysplastic syndromes. In this retrospective study, we analyse data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option due to its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy
Conclusion We suggest routine use of peg-GCSF is an acceptable alternative to daily GCSF, for patients in whom da-EPOCH-R is selected as first-line treatment for aggressive B-NHL. Micro-Abstract Dose-adjusted EPOCH-R (etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab) remains a therapeutic option for high-risk, aggressive B-cell non-Hodgkin lymphoma subsets. Whether pegylated granulocyte colony-stimulating factor (peg-GCSF) affords similar efficacy compared with daily granulocyte colony-stimulating factor is unknown. In this study we found similar attained dose level and patient outco...
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Real-world Case Series of Consecutive Patients Treated by a Single Multidisciplinary Team in the East of England From 1999 to 2015
Publication date: December 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 12 Author(s): Jessica C. Griffin, Shalal Sadullah, Lazlo Igali, Nimish K. Shah, Jennifer Z. Wimperis, Kristian M. Bowles (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Increased Mortality Among Patients With Acute Leukemia Admitted on Weekends Compared to Weekdays
Conclusion There was significantly increased mortality among weekend admissions for acute leukemia. Mortality was reduced among patients admitted to teaching hospitals. Micro-Abstract The mortality of patients admitted on the weekends was compared with that on weekdays. There was significantly increased mortality among acute leukemia patients admitted on a weekend. We also conclude that patients admitted to teaching hospitals have a better outcome. This study emphasizes the importance of availability of resources and early presentation to tertiary care centers for acute leukemia patients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Sepsis and Acute Myeloid Leukemia: A  Population-Level Study of Comparative Outcomes of Patients Discharged From Texas Hospitals
Conclusion Patients with AML had a higher sepsis incidence and higher mortality rates overall, especially in relation to stem-cell transplant recipients and those with other types of cancer. Clinical trials are needed to determine whether early intervention or treatment in specialized centers could improve outcomes and reduce costs of care, particularly in the management of serious complications such as sepsis. Micro-Abstract We reviewed outcomes of patients with acute myeloid leukemia (AML) and sepsis in Texas. AML patients (0.25% of > 2 million discharges) had a higher incidence of sepsis (16% vs. 4%) and of sepsi...
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Improving Provision of Care for Long-term Survivors of Lymphoma
Publication date: December 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 12 Author(s): Sabino Ciavarella, Carla Minoia, Angela Maria Quinto, Stefano Oliva, Santa Carbonara, Claudia Cormio, Maria Christina Cox, Elena Bravo, Filippo Santoro, Mariarosaria Napolitano, Michele Spina, Giacomo Loseto, Attilio Guarini The progressive improvement of lymphoma therapies has led to a significant prolongation of patient survival and life expectancy. However, lymphoma survivors are at high risk of experiencing a range of early and late adverse effects associated with the extent of treatment exposure. Among these,...
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia
Conclusion CLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML. Micro-Abstract Given the lack of standard salvage chemotherapy regimen for relapsed or refractory (RR) acute myeloid leukemia (AML), a phase 2 clinical study of cladribine, cytarabine, G-CSF (CLAG) regimen in combination with imatinib mesylate (IM) in patients with RR-AML was conducted at the Moffitt Cancer Center. Between August 2009 and April 2011, 38 patients were treated and the overall response rate was 37% with a median overall survival of 11.1 month. Among responders, 8/14 patients proceeded to allogeneic h...
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement
Conclusion CNS-directed high-dose chemotherapy and ASCT provides durable remission for patients with synchronous aggressive lymphoma and should be strongly considered as consolidative therapy for eligible patients with systemic NHL with CNS involvement in first complete remission. Micro-Abstract Systemic non-Hodgkin lymphoma with synchronous central nervous system involvement traditionally carries a poor prognosis. We found encouraging results with the use of high-dose chemotherapy and autologous stem cell transplantation as consolidation for patients in first complete remission. Central nervous system-directed conditionin...
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients
Conclusion PCPI is a practical method that predicts OS in newly diagnosed myeloma and facilitates broader use of MM cell proliferation for risk stratification. Micro-Abstract The plasma cell labeling index (PCLI) prognosticates survival in multiple myeloma (MM) yet is underutilized as a result of its technical difficulty. We retrospectively evaluated multiplex immunohistochemistry (mIHC) in 151 newly diagnosed patients as a clinically feasible alternative to PCLI. The mIHC correlated with PCLI results and was predictive of overall survival for MM. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis
Conclusion In older patients (age ≥ 60 years) with stage I/II HL, the combination of CT plus consolidative RT resulted in improved OS compared with monotherapy. However, the use of combination therapy in this age group seems suboptimal. This could be, in part, secondary to comorbidities limiting the use of CT plus RT in the elderly. Micro-Abstract Early-stage Hodgkin lymphoma is a highly curable malignancy. However, the outcomes for elderly patients have remained suboptimal. We conducted a retrospective study using the National Cancer Database to assess the therapies used for elderly patients with early-stage Hodgk...
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

SOHO state-of-the-art update and next questions: MPN
Publication date: Available online 2 December 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Prithviraj Bose, Jason Gotlib, Claire N. Harrison, Srdan Verstovsek The discovery of the activating JAK2 V617F mutation in 2005 in the majority of patients with the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) spurred intense interest in research into these disorders, culminating in the identification of activating mutations in MPL in 2006 and indels in CALR in 2013, thus providing additional mechanistic explanations for the universal activation of Janus kinase-signal transducer and ac...
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Characterizing autoimmune disease-associated diffuse large B cell lymphoma in a SEER-Medicare cohort
Conclusions In this retrospective claims-based cohort of older patients with DLBCL, concomitant AI disease was uncommon and was more likely to occur in female DLBCL patients, which likely reflects the higher incidence of AI disease in women. The possibility of lower LRS for SLE patients should be explored in future studies. Teaser We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to characterize patterns of presentation, treatment, and survival in older DLBCL patients with concomitant autoimmune disease. DLBCL patients with autoimmune disease were more likely to be female, but otherwis...
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence in Situ Hybridization/Cytogenetics: A Real-World Clinical Experience in the Connect CLL Registry
Conclusion This study shows that prognostic cytogenetic/FISH testing is infrequently performed and that patients with unfavorable-risk genetics treated with immunochemotherapy combinations have worse outcomes. This underscores the importance of performing prognostic genetic testing in all CLL patients to guide treatment. Teaser Prognostic genetic testing can guide treatment decisions and predict outcomes for patients with chronic lymphocytic leukemia (CLL). Among 1,494 patients with CLL treated in the community setting, prognostic genetic testing was infrequently performed and outcomes were inferior for patients with unfav...
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

Analysis of Real-World Data on Postremission Therapy for Acute Myeloid Leukemia with Intermediate Risk Cytogenetics in First Complete Remission
Publication date: Available online 7 December 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Jan Vydra, Cyril Šálek, Jiří Schwarz, Pavel Žák, Jan Novák, Veronika Petečuková, Pavla Pecherková, Jiří Mayer, Petr Cetkovský, Zdeněk Ráčil (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 16, 2017 Category: Cancer & Oncology Source Type: research

A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma
Publication date: Available online 13 October 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29,...
Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research

Early relapse for Multiple Myeloma patients undergoing single auto-SCT: A single center experience
Publication date: Available online 1 November 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Holly Lee, Peter Duggan, Ahsan Chaudhry, Paola Neri, Jason Tay, Fariborz Rashid-Kolvear, Nizar J. Bahlis, Victor H. Jimenez-Zepeda Multiple myeloma is a heterogeneous disease with diverse clinical courses and patient outcomes. While the introduction of novel agents (NA) has improved the overall survival (OS) of myeloma patients, reports have highlighted that there persists a subset of patients who undergo early relapse (ER) whose prognosis is significantly poorer than patients with longer therapy response. The purpo...
Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research

FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients
Conclusion Our data seem to confirm the value of FLAG-Ida in this setting and might suggest its best usage as bridge therapy for patients awaiting allotransplantation. Micro-Abstract Allotransplant is crucial for improving survival in refractory/first relapsed AML patients. An overall response was achieved in 48 patients (44% of the whole group) with FLAG-Ida chemotherapy approach. 24 of 48 responders underwent allotransplantation obtaining a median OS of 60 months. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research

State of the Art Update and Next Questions: Acute Myeloid Leukemia
Publication date: November 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 11 Author(s): Kendra Sweet, Jeffrey Lancet As our general understanding regarding the complex nature of acute myeloid leukemia (AML) is expanding, so is our ability to translate this biological data into clinically relevant information. The use of whole genome and whole exome sequencing has begun to shed light on the importance of a variety of somatic mutations that are frequently identified in AML. In turn, this has allowed the field to incorporate mutational data into prognostic classifications which can guide treatment decis...
Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research

Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma
Conclusion Overall effectiveness and tolerability outcomes were similar between modified hyperCVAD and bortezomib-hyperCAD, with both regimens demonstrating an impressive response rate among refractory and heavily pre-treated patients with relapsed MM. Teaser Despite the availability of novel treatments for multiple myeloma, resistance to chemotherapy inevitably develops. We retrospectively reviewed the outcomes of patients with relapsed and/or refractory disease treated with modified hyperCVAD (n = 15) or bortezomib-hyperCAD (n = 18). Effectiveness and safety outcomes were similar in each group, with the entire cohort of ...
Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research

VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study
Conclusions Long-term outcomes with VcR-CVAD are comparable with more intensive inductions and consolidation approaches. MCL is biologically heterogeneous and durable remission can be achieved with intermediate intensity therapy. Maintenance rituximab appears to contribute to these excellent outcomes. Teaser VcR-CVAD with maintenance rituximab is an intermediate-intensity regimen for older and younger mantle cell lymphoma (MCL) patients. Thirty patients were treated, with primary end point of response and secondary endpoints of progression-free and overall survival. After a median follow-up of 7.8 years, no relapses were o...
Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research

A Phase II Trial of Rituximab in Combination with Pegfilgrastim in Patients with Indolent B-Cell Non-Hodgkin ’s Lymphoma
Conclusion Pegfilgrastim-rituximab combination was well tolerated with favorable outcomes when compared to historical controls. A shorter time to peak oxidative burst was associated with higher CR rates and longer PFS. Our results support further evaluation of strategies that enhance the innate immune system to improve rituximab activity in B-NHL. Teaser This phase 2 study demonstrates that augmenting neutrophil function by addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin’s lymphomas (B-NHL) while retaining its excellent safety profile. Strategies to boost the...
Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research

Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma
Publication date: Available online 7 November 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Fernando Cabanillas, Bijal Shah The management of diffuse large B-cell lymphoma (DLBCL) has been gradually evolving since the discovery of its 2 major forms, the germinal center B-like (GCB) and activated B-cell (ABC) types. Although the reference standard for the identification of these cell types is considered gene expression profiling (GEP), currently the only method commercially available is immunohistochemistry (IHC). The application of various IHC-based algorithms and their correlation with GEP and clinical ou...
Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research

Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)
Publication date: Available online 14 November 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, L. Jeffrey Medeiros, Michael J. Overman, Jorge E. Romaguera, Loretta Nastoupil, Michael Wang, Fredrick B. Hagemeister, Alma Rodriguez, Yasuhiro Oki, Jason Westin, Francesco Turturro, Sattva S. Neelapu, Luis Fayad The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. This is a case series of 45 patients with FLG3 treated with frontline R-CHOP and observed for an extended time interval. The overall response rate was 100% and the m...
Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research

A Systematic Review of Treatments for Relapsed/Refractory Mantle Cell Lymphoma
Publication date: Available online 13 October 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson A systematic literature review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. Criteria for inclusion of trials were established prior to the literature review. A search of Medline, Embase and the Cochrane library databases was conducted to identify phase II or III randomised controlled trials (RCTs), published from January 1s...
Source: Clinical Lymphoma Myeloma and Leukemia - October 14, 2017 Category: Cancer & Oncology Source Type: research

Allogeneic hematopoietic cell transplantation for Richter syndrome: a single-center experience
Conclusion Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome who demonstrate an objective response prior to allografting. Patients must be referred to transplant centers as soon as diagnosis is confirmed to evaluate candidacy for the procedure and identify a suitable donor in a timely manner. Teaser ⁃ Allogeneic hematopoietic cell transplantation is an effective therapy in patients with Richter syndrome. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 13, 2017 Category: Cancer & Oncology Source Type: research

Management of Advanced and Relapsed/Refractory Extra-Nodal Natural Killer T-Cell Lymphoma (ENKL): An Analysis of Stem Cell Transplant and Chemotherapy Outcomes
Publication date: Available online 12 October 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Jonathan E. Brammer, Dai Chihara, L. Michelle Poon, Paolo Caimi, Marcos de Lima, Celina Ledesma, Gabriela Rondon, Stefan O. Ciurea, Yago Nieto, Michele Fanale, Bouthaina Dabaja, Richard T. Maziarz, Richard E. Champlin, Chitra Hosing, Yasuhiro Oki (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 13, 2017 Category: Cancer & Oncology Source Type: research

Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Newly Diagnosed Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Lucia Masarova, Hagop Kantarjian, Srdan Verstovsek (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Lucia Masarova, Hagop M. Kantarjian, Srdan Verstovsek (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Molecular Pathophysiology of Myeloma and Clinical Applications
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Kenneth Anderson (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Intercorrelation of Expression of CD56, CD117, CD33, CD20 Antigens with Survival Rates in Patients with Multiple Myeloma in Gomel Region in Belarus
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Z. Kozich, V. Martinkov, Z. Pugacheva, L. Smirnova (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Characteristics and Outcomes of Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adult Patients: A Single-Center Experience
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Rita Assi, Prajwal Boddu, Tapan Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Koichi Takahashi, Marina Konopleva, Abdallah Abou Zahr, Courtney DiNardo, Gautam Borthakur, Nitin Jain, Naveen Pemmaraju, Jing Ning, Sherry Pierce, William Wierda, Jorge Cortes, Hagop Kantarjian, Naval Daver (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Hee-Je Kim, Hea-Lyun Yoo, Won-Sik Lee, Hyeong-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sukjoong Oh, Sung Hyun Kim, Jeong-A. Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Sung-Eun Lee, Dong-Wook Kim (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Long-Term Outcomes of Early CP CML Patients who have Achieved CCyR but Not MMR after 24 Months on Frontline Imatinib Therapy
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Sung-Eun Lee, Won-Sik Lee, Hyeong-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sukjoong Oh, Sung Hyun Kim, Jeong-A. Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Dong-Wook Kim (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Kiran Naqvi, Jorge Cortes, Jeffrey Skinner, Elias Jabbour, Naveen Pemmaraju, Gautam Borthakur, Zeev Estrov, Prithviraj Bose, Philip Thompson, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Michael J. Mauro, Jorge E. Cortes, Andreas Hochhaus, Neil P. Shah, Ehab Atallah, Mena Abaskharoun, Oumar Sy, Giuseppe Saglio (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy  of Patients with CLL with Mutated IGHV and Without Deletion 17p
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Nitin Jain, Philip Thompson, Jan Burger, Gautam Borthakur, Prithviraj Bose, Zeev Estrov, Alessandra Ferrajoli, Koichi Takahashi, Naveen Garg, Xuemei Wang, Varsha Gandhi, William Plunkett, Rashmi Kanagal-Shamanna, Keyur Patel, Wanda Lopez, Hagop Kantarjian, Susan O'Brien, Michael Keating, William Wierda (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Paolo Strati, Michael J. Keating, Jan A. Burger, Susan M. O'Brien, William G. Wierda, Zeev Estrov, Gracy Zacharian, Alessandra Ferrajoli (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Riccardo Moia, Fary Diop, Chiara Favini, Elisa Spaccarotella, Lorenzo De Paoli, Alessio Bruscaggin, Valeria Spina, Michaela Cerri, Clara Deambrogi, Ahad Ahmed Kodipad, Simone Favini, Sruthi Sagiraju, Clive Jabangwe, Francesca Romana Mauro, Ilaria Del Giudice, Francesco Forconi, Agostino Cortelezzi, Francesco Zaja, Carlo Visco, Annalisa Chiarenza, Gian Matteo Rigolin, Roberto Marasca, Marta Coscia, Omar Perbellini, Alessandra Tedeschi, Luca Laurenti, Marina Motta, Giovanni Del Poeta, Antonio Cuneo, Valte...
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Betül Oran, Guillermo Garcia-Manero, Rima M. Saliba, Gheath Al-Atrash, Elias Jabbour, Uday Popat, Farhad Ravandi, Amin Alousi, Tapan Kadia, Marina Konopleva, Courtney Dinardo, Katy Rezvani, Elizabeth J. Shpall, Padmanee Sharma, Richard E. Champlin, Hagop M. Kantarjian, Naval Daver (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Sang Kim, Vickie Shannon, Ajay Sheshadri, Hagop Kantarjian, Guillermo Garcia-Manero, Jin Im, Farhad Ravandi, Aung Naing, Padmanee Sharma, Dimitrios Kontoyiannis, Andrew Futreal, Naval Daver (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML)
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Rita Assi, Mark Brandt, Sherry Pierce, Tauna Gordon, Naveen Pemmaraju, Michael Andreeff, Jing Ning, Steven Kornblau, Tapan Kadia, Wilmer Flores, Jairo Matthews, Courtney Dinardo, Marina Konopleva, James Allison, Padmanee Sharma, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Targeting Unc-51 Like Autophagy Activating Kinase 1 (ULK1) in Acute Myeloid Leukemia (AML)
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Seemana Bhattacharya, Sujan Piya, Teresa McQueen, Marina Konopleva, Michael Andreeff, Gautam Borthakur (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Naval Daver, Rita Assi, Farhad Ravandi, Guillermo Garcia-Manero, Elias Jabbour, Courtney D. DiNardo, Tapan M. Kadia, Jing Ning, Graciela Nogueras-Gonzalez, Sherry Pierce, Dan Gombos, Steven Kornblau, Marina Konopleva, Mary Kelly, Gautam Borthakur, Weiguo Zhang, Jorge Cortes, Hagop Kantarjian, Michael Andreeff (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Naval Daver, Prajwal Boddu, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Courtney DiNardo, Marina Konopleva, Naveen Pemmaraju, Tapan Kadia, Nitin Jain, Sherry Pierce, Nawar Hussain, Jing Ning, Graciela Nogueras-Gonzalez, Sreyashi Basu, Jorge Cortes, Padmanee Sharma, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5 + Ida), and 5 days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian Design
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Kiran Naqvi, Garciela Nogueras Gonzalez, Cora Cheung, Naveen Pemmaraju, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Maro Ohanian, Nitin Jain, Koichi Takahashi, Yesid Alvarado, Marina Konopleva, Xuelin Huang, Jorge Cortes, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Evaluation of Fluoroquinolone Versus Other Antibiotic Prophylaxis Strategies in Adult Patients with AML Undergoing Induction Chemotherapy
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Telyssa Anderson, Samuel L. Aitken, Kayleigh Marx, Frank P. Tverdek (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Caitlin R. Rausch, Courtney D. DiNardo, Tapan Kadia, Koichi Takahashi, Nitin Jain, Christopher Benton, Philip Thompson, Maro Ohanian, Wendy Covert, Morgan Mace, Kayleigh R. Marx, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Jorge Cortes, Guillermo Garcia-Manero, Farhad Ravandi, Marina Konopleva, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Outcomes with Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine as Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Prajwal Boddu, Nitin Jain, Farhad Ravandi, Guillermo Garcia Manero, Gautam Borthakur, Tapan Kadia, Elias J. Jabbour, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Yesid Alvarado, Koichi Takahashi, Christopher Benton, Allison Pike, Sherry Pierce, Jorge E. Cortes, Hagop M. Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with  FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Mahesh Swaminathan, Hagop Kantarjian, Naval Daver, Gautam Borthakur, Maro Ohanian, Tapan Kadia, Courtney DiNardo, Nitin Jain, Zeev Estrov, Alessandra Ferrajoli, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naveen Pemmaraju, Elias Jabbour, Yesid Alvarado, William Wierda, Maria Rhona Pinsoy, Farhad Ravandi, Jorge Cortes (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research

Phosphotyrosine-Based Phosphoproteomics of a Panel AML Cell Lines Reveals Oncogenic Signaling and Hyperactive Tyrosine Kinases as Targets for Treatment
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Carolien van Alphen, Jacqueline Cloos, Sander R. Piersma, Jaco C. Knol, Thang V. Pham, Johan van Meerloo, Gert J. Ossenkoppele, Henk M.W. Verheul, Jeroen J.W.M. Janssen, Connie R. Jimenez (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research